Ambesten Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 370.39%
- Ebitda 388.54%
- Net Worth 21.50%
- Total Assets 2902.92%
About Ambesten Pharmaceuticals
Ambesten Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 June 2015 (Nine years and seven months 8 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Prasada Gollapudi and Subhashini Muddana serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U33111TG2015PTC099435
- Company No.
099435
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Ambesten Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prasada Gollapudi  | Director | 23-Jun-2015 | Current |
| Subhashini Muddana | Director | 03-Dec-2015 | Current |
Financial Performance of Ambesten Pharmaceuticals.
Ambesten Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 370.39% increase in profit. The company's net worth Soared by an impressive increase of 21.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ambesten Pharmaceuticals?
In 2023, Ambesten Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Puritan Labs Private LimitedPrasada Gollapudi and Subhashini Muddana are mutual person
Extrovis Private LimitedPrasada Gollapudi is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ambesten Pharmaceuticals?
Unlock and access historical data on people associated with Ambesten Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ambesten Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ambesten Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
